President Trump and FDA commissioner Stephen Hahn at the White House in Washington on March 19, 2020 (Yuri Gripas, Sipa via AP Images)
April 21, 2020 02:03 PM EDTUpdated April 22, 10:33 AM
R&D
Coronavirus

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

John Carroll

Editor & Founder

Just weeks fol­low­ing the FDA’s emer­gency ap­proval of hy­drox­y­chloro­quine af­ter Pres­i­dent Trump re­peat­ed­ly ad­vo­cat­ed its use for Covid-19, new da­ta from a quick VA study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times